Leerink Swann Upgrades Intellia Therapeutics to Outperform

Brokerage firm Leerink Swann Upgrades its rating on Intellia Therapeutics(NASDAQ:NTLA). The shares have been rated Outperform. Previously, the analysts had a Market Perform rating on the shares. The rating by Leerink Swann was issued on Aug 5, 2016.

In a different note, On Aug 5, 2016, Jefferies said it Upgrades its rating on Intellia Therapeutics. The shares have been rated ‘Buy’ by the firm. Credit Suisse said it Initiates Coverage on Intellia Therapeutics, according to a research note issued on May 31, 2016. The shares have been rated ‘Outperform’ by the firm. Wedbush said it Initiates Coverage on Intellia Therapeutics, according to a research note issued on May 31, 2016. The shares have been rated ‘Outperform’ by the firm. Jefferies said it Initiates Coverage on Intellia Therapeutics, according to a research note issued on May 31, 2016. The shares have been rated ‘Hold’ by the firm. Leerink Swann said it Initiates Coverage on Intellia Therapeutics, according to a research note issued on May 31, 2016. The shares have been rated ‘Market Perform’ by the firm.

Intellia Therapeutics(NTLA) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $4.21M. Analysts had an estimated revenue of $5.81M. Earnings per share were $-0.36. Analysts had estimated an EPS of $-0.16.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Intellia Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intellia Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.